# Viking Therapeutics (VKTX): Analyst Ratings Indicate a Potential Upside of Over 194%

- Link: https://www.directorstalkinterviews.com/viking-therapeutics-vktx-analyst-ratings-indicate-a-potential-upside-of-over-194/4121236866
- Published: 2026-01-27T11:06:34+00:00
- Author: Madison Wilson

Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company,
is garnering significant attention from investors with its promising drug pipeline
and substantial potential upside. With a market capitalization of $3.59 billion,
Viking Therapeutics operates within the healthcare sector’s biotechnology industry,
focusing on novel therapies for metabolic and endocrine disorders.

The company’s lead compound, VK2809, is an orally available tissue and receptor-
subtype selective agonist of the thyroid hormone receptor beta (TRß), currently 
in Phase IIb clinical trials aimed at treating non-alcoholic steatohepatitis (NASH)
and non-alcoholic fatty liver disease (NAFLD). Additionally, Viking is developing
several other promising candidates, including VK5211 for hip fracture recovery and
VK2735, a novel dual agonist for metabolic disorders.

Currently trading at $31.73, Viking’s stock has shown resilience, maintaining a 
position within its 52-week range of $19.98 to $42.09. Despite a recent marginal
price decline of 0.49 points, the stock’s technical indicators paint a picture of
potential recovery. The 50-day moving average of $35.25 suggests near-term volatility,
while the 200-day moving average of $30.97 provides a stable foundation. The RSI(
14) of 39.12 implies that the stock is nearing oversold territory, potentially signaling
a buying opportunity for value-seeking investors.

Analyst sentiment towards Viking Therapeutics is overwhelmingly positive, with 17
buy ratings, one hold rating, and no sell ratings. The average target price of $
93.39 underscores a remarkable potential upside of 194.32%, with the target price
range extending from $36.00 to an ambitious $125.00. This optimism is fueled by 
the company’s strategic focus on high-demand therapeutic areas and its robust pipeline
of drug candidates.

However, investors should note the financial metrics, which reflect the inherent
challenges of a clinical-stage biopharmaceutical firm. Viking reported an EPS of-
2.12 and a return on equity of -29.23%, indicating that the company is not yet profitable.
The negative free cash flow of approximately $150.9 million further emphasizes the
capital-intensive nature of its R&D activities. Moreover, with the absence of revenue
growth and a P/E ratio, traditional valuation metrics are not applicable at this
stage.

Despite these financial hurdles, Viking’s innovative approach and potential for 
groundbreaking therapies make it a compelling candidate for investors with a high-
risk tolerance and a focus on long-term growth. As the company progresses through
clinical trials and moves closer to potential regulatory approvals, the milestones
achieved could significantly impact its market valuation and investor sentiment.

For those considering an investment in Viking Therapeutics, the primary appeal lies
in its high potential upside and the strategic advancements in its drug development
pipeline. Investors should remain vigilant, keeping an eye on clinical trial results
and regulatory updates, which are key catalysts for this biotech stock’s future 
performance.

Share on:
